• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Changes in Hepatocellular Carcinoma Surveillance and Risk Factors for Noncompletion in the Veterans Health Administration Cohort During the Coronavirus Disease 2019 Pandemic.

作者信息

Mahmud Nadim, Kaplan David E, Goldberg David S, Taddei Tamar H, Serper Marina

机构信息

Division of Gastroenterology and Hepatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania; Gastroenterology Section, Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania; Leonard Davis Institute of Health Economics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania; Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, Pennsylvania.

Division of Gastroenterology and Hepatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania; Gastroenterology Section, Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania.

出版信息

Gastroenterology. 2021 May;160(6):2162-2164.e3. doi: 10.1053/j.gastro.2021.01.007. Epub 2021 Jan 9.

DOI:10.1053/j.gastro.2021.01.007
PMID:33434604
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8142896/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5f4/9188434/9440e0dab397/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5f4/9188434/9440e0dab397/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5f4/9188434/9440e0dab397/gr1_lrg.jpg

相似文献

1
Changes in Hepatocellular Carcinoma Surveillance and Risk Factors for Noncompletion in the Veterans Health Administration Cohort During the Coronavirus Disease 2019 Pandemic.2019年冠状病毒病大流行期间退伍军人健康管理局队列中肝细胞癌监测的变化及未完成监测的风险因素
Gastroenterology. 2021 May;160(6):2162-2164.e3. doi: 10.1053/j.gastro.2021.01.007. Epub 2021 Jan 9.
2
Increased Diagnosis of Hepatocellular Carcinoma in Hospitalized Patients with Alcohol Related Hepatitis after the Covid-19 Outbreak: A Global Multi-Center Propensity Matched Analysis.新冠疫情爆发后住院酒精性肝炎患者肝细胞癌诊断增加：一项全球多中心倾向匹配分析
Clin Gastroenterol Hepatol. 2021 Nov;19(11):2450-2451.e1. doi: 10.1016/j.cgh.2021.05.010. Epub 2021 May 11.
3
Identification of SARS-CoV-2 Proteins Binding Human mRNAs As a Novel Signature Predicting Overall Survival in Hepatocellular Carcinoma.鉴定与人类 mRNA 结合的 SARS-CoV-2 蛋白作为一种新型标志物，预测肝细胞癌的总生存期。
DNA Cell Biol. 2021 Feb;40(2):359-372. doi: 10.1089/dna.2020.6278. Epub 2020 Dec 4.
4
COVID-19 pandemic: Impact on the management of patients with hepatocellular carcinoma at a tertiary care hospital.COVID-19 大流行：对一家三级保健医院肝细胞癌患者管理的影响。
PLoS One. 2021 Aug 26;16(8):e0256544. doi: 10.1371/journal.pone.0256544. eCollection 2021.
5
Worldwide management of hepatocellular carcinoma during the COVID-19 pandemic.COVID-19 大流行期间的全球肝细胞癌管理。
World J Gastroenterol. 2021 Jul 7;27(25):3780-3789. doi: 10.3748/wjg.v27.i25.3780.
6
Effect of travel distance and rurality of residence on initial surveillance for hepatocellular carcinoma in VA primary care patient with cirrhosis.距离和居住的农村性对退伍军人事务部初级保健有肝硬化的肝细胞癌患者初始监测的影响。
Health Serv Res. 2020 Feb;55(1):103-112. doi: 10.1111/1475-6773.13241. Epub 2019 Nov 25.
7
Low incidence of COVID-19 in a prospective cohort of patients with liver cirrhosis and hepatocellular carcinoma treated at a tertiary medical center during the 2020 pandemic.2020 年大流行期间，在一家三级医疗中心接受治疗的肝硬化和肝细胞癌患者前瞻性队列中 COVID-19 的发病率较低。
PLoS One. 2021 Dec 23;16(12):e0258450. doi: 10.1371/journal.pone.0258450. eCollection 2021.
8
Management of hepatocellular carcinoma in the time of COVID-19.2019冠状病毒病时期肝细胞癌的管理
Ann Oncol. 2020 Aug;31(8):1084-1085. doi: 10.1016/j.annonc.2020.04.007. Epub 2020 Apr 21.
9
Five recommendations for loco-regional treatments of hepatocellular carcinoma during the COVID-19 pandemic.COVID-19大流行期间肝细胞癌局部区域治疗的五项建议。
Dig Liver Dis. 2020 Sep;52(9):950-952. doi: 10.1016/j.dld.2020.05.035. Epub 2020 Jun 16.
10
Hepatocellular Carcinoma in the COVID-19 Era: Primetime for Stereotactic Body Radiotherapy and a Lesson for the Future?COVID-19 时代的肝细胞癌：立体定向体部放疗的黄金时期及对未来的启示？
Oncologist. 2020 Aug;25(8):e1249-e1250. doi: 10.1634/theoncologist.2020-0416. Epub 2020 Jun 23.

引用本文的文献

1
Clinicopathological Study on Morphological Subtypes of Hepatocellular Carcinoma: A Single Tertiary Referral Center Experience.肝细胞癌形态学亚型的临床病理研究：单中心三级转诊中心经验
Cancer Rep (Hoboken). 2025 Feb;8(2):e70127. doi: 10.1002/cnr2.70127.
2
Predicting long-term survival among patients with HCC.预测 HCC 患者的长期生存率。
Hepatol Commun. 2024 Nov 4;8(11). doi: 10.1097/HC9.0000000000000581. eCollection 2024 Nov 1.
3
Decreased Completion of Ordered Laboratories and Imaging in Telehealth Compared With In-person Hepatology Encounters.

本文引用的文献

1
Declining Cirrhosis Hospitalizations in the Wake of the COVID-19 Pandemic: A National Cohort Study.新冠疫情后肝硬化住院率下降：一项全国队列研究
Gastroenterology. 2020 Sep;159(3):1134-1136.e3. doi: 10.1053/j.gastro.2020.05.005. Epub 2020 May 6.
2
The COVID-19 pandemic will have a long-lasting impact on the quality of cirrhosis care.新冠疫情将对肝硬化治疗质量产生长期影响。
J Hepatol. 2020 Aug;73(2):441-445. doi: 10.1016/j.jhep.2020.04.005. Epub 2020 Apr 13.
3
Incidence and Mortality of Acute-on-Chronic Liver Failure Using Two Definitions in Patients with Compensated Cirrhosis.
与面对面肝病诊疗相比，远程医疗中所安排的实验室检查和影像学检查的完成率降低。
J Clin Gastroenterol. 2025 Apr 1;59(4):354-360. doi: 10.1097/MCG.0000000000002023.
4
Impact of the Early COVID-19 Pandemic on Incidence and Outcomes of Hepatocellular Carcinoma in the United States.早期 COVID-19 大流行对美国肝细胞癌发病率和结局的影响。
Clin Transl Gastroenterol. 2024 Jul 1;15(7):e00723. doi: 10.14309/ctg.0000000000000723.
5
Assessing Adherence to US LI-RADS Follow-up Recommendations in Vulnerable Patients Undergoing Hepatocellular Carcinoma Surveillance.评估在进行肝细胞癌监测的脆弱患者中，对美国 LI-RADS 随访建议的依从性。
Radiol Imaging Cancer. 2024 Jan;6(1):e230118. doi: 10.1148/rycan.230118.
6
SARS-CoV-2 Infection and Liver Disease: A Review of Pathogenesis and Outcomes.严重急性呼吸综合征冠状病毒 2 感染与肝脏疾病：发病机制和结局的综述。
Gut Liver. 2023 Jan 15;17(1):12-23. doi: 10.5009/gnl220327. Epub 2022 Dec 2.
7
Impact of SARS-CoV-2 Pandemic on the Management of Patients with Hepatocellular Carcinoma.严重急性呼吸综合征冠状病毒2型大流行对肝细胞癌患者管理的影响
J Clin Med. 2022 Jul 31;11(15):4475. doi: 10.3390/jcm11154475.
8
Coronavirus Disease 2019 Vaccinations in Patients With Chronic Liver Disease and Liver Transplant Recipients: An Update.2019年冠状病毒病在慢性肝病患者和肝移植受者中的疫苗接种：最新情况
Front Med (Lausanne). 2022 Jun 22;9:924454. doi: 10.3389/fmed.2022.924454. eCollection 2022.
9
Updates in Telemedicine for Gastroenterology Practices in the United States.美国胃肠病学实践中的远程医疗更新
Clin Gastroenterol Hepatol. 2022 Jul;20(7):1432-1435. doi: 10.1016/j.cgh.2022.03.024. Epub 2022 Mar 29.
10
Accurate long-term prediction of death for patients with cirrhosis.肝硬化患者死亡的准确长期预测。
Hepatology. 2022 Sep;76(3):700-711. doi: 10.1002/hep.32457. Epub 2022 Apr 1.
两种定义下代偿性肝硬化患者慢加急性肝衰竭的发生率和死亡率。
Hepatology. 2019 May;69(5):2150-2163. doi: 10.1002/hep.30494. Epub 2019 Mar 20.
4
AASLD guidelines for the treatment of hepatocellular carcinoma.美国肝病研究学会肝细胞癌治疗指南。
Hepatology. 2018 Jan;67(1):358-380. doi: 10.1002/hep.29086.
5
Identifying barriers to hepatocellular carcinoma surveillance in a national sample of patients with cirrhosis.在全国肝硬化患者样本中识别肝细胞癌监测的障碍。
Hepatology. 2017 Mar;65(3):864-874. doi: 10.1002/hep.28765. Epub 2016 Oct 5.
6
Development and Performance of an Algorithm to Estimate the Child-Turcotte-Pugh Score From a National Electronic Healthcare Database.一种从国家电子医疗数据库估算Child-Turcotte-Pugh评分的算法的开发与性能
Clin Gastroenterol Hepatol. 2015 Dec;13(13):2333-41.e1-6. doi: 10.1016/j.cgh.2015.07.010. Epub 2015 Jul 15.
7
Screening process failures for hepatocellular carcinoma.肝细胞癌的筛查流程失败。
J Natl Compr Canc Netw. 2014 Mar 1;12(3):375-82. doi: 10.6004/jnccn.2014.0039.
8
Detection of hepatocellular carcinoma at advanced stages among patients in the HALT-C trial: where did surveillance fail?在 HALT-C 试验中，晚期肝细胞癌患者的检测：监测在哪里失败了？
Am J Gastroenterol. 2013 Mar;108(3):425-32. doi: 10.1038/ajg.2012.449. Epub 2013 Jan 22.
9
Validation of three coding algorithms to identify patients with end-stage liver disease in an administrative database.在一个管理数据库中验证三种编码算法以识别终末期肝病患者。
Pharmacoepidemiol Drug Saf. 2012 Jul;21(7):765-769. doi: 10.1002/pds.3290. Epub 2012 Jun 4.
10
Validity of diagnostic codes and liver-related laboratory abnormalities to identify hepatic decompensation events in the Veterans Aging Cohort Study.诊断代码和与肝脏相关的实验室异常在退伍军人老龄化队列研究中识别肝失代偿事件的有效性。
Pharmacoepidemiol Drug Saf. 2011 Jul;20(7):689-99. doi: 10.1002/pds.2148. Epub 2011 May 27.